-
1Academic Journal
المؤلفون: F. A. Abbasov, G. V. Zemtsova, P. A. Popov, K. I. Chekhonatskaya, D. V. Kukhno, M. M. Severova, M. V. Shmyreva, A. A. Kindarova, D. Yu. Schekochikhin, Ф. А. Аббасов, Г. В. Земцова, П. А. Попов, К. И. Чехонацкая, Д. В. Кухно, М. М. Северова, М. В. Шмырева, А. А. Киндарова, Д. Ю. Щекочихин
المصدر: Neuromuscular Diseases; Том 13, № 2 (2023); 72-82 ; Нервно-мышечные болезни; Том 13, № 2 (2023); 72-82 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2023-13-2
مصطلحات موضوعية: креатинфосфокиназа, polymyositis, anti‑SRP, inflammatory myopathies, creatine phosphokinase, полимиозит, анти‑SRP, воспалительные миопатии
وصف الملف: application/pdf
Relation: https://nmb.abvpress.ru/jour/article/view/545/352; Malik A., Hayat G., Kalia J.S. et al. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol 2016;7:64. DOI:10.3389/fneur.2016.00064; Pinal-Fernandez I., Casal-Dominguez M., Mammen A.L. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep 2018;20(4):21. DOI:10.1007/s11926-018-0732-6; McGrath E.R., Doughty C.T., Amato A.A. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics 2018;15(4):976–94. DOI:10.1007/s13311-018-00676-2; Ghirardello A., Borella E., Beggio M. et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights 2014;5(3):69–75. DOI:10.1007/s13317-014-0060-4; Betteridge Z., McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280(1):8–23. DOI:10.1111/joim.12451; Антелава О.А. Полимиозит/дерматомиозит: дифференциаль ная диагностика. Научно-практическая ревматология 2016;54(2):191–8. DOI:10.14412/1995-4484-2016-191-198; Rodríguez-Muguruza S., Lozano-Ramos I., Coll-Canti J. et al. Anti-SRP auto-antibodies are not specific for myositis: report of 8 cases. Joint Bone Spine 2017;84(1):103–5. DOI:10.1016/j.jbspin.2015.12.005; Satoh M., Tanaka S., Ceribelli A. et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017;52(1):1–19. DOI:10.1007/s12016-015-8510-y; Wang L., Liu L., Hao H. et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 2014;24(4):335–41. DOI:10.1016/j.nmd.2014.01.002; Suzuki S., Nishikawa A., Kuwana M. et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10:61. DOI:10.1186/s13023-015-0277-y; Allenbach Y., Mammen A.L., Benveniste O. et al. Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord 2018;28(1):87–99. DOI:10.1016/j.nmd.2017.09.016; Pinal-Fernandez I., Casal-Dominguez M., Carrino J.A. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017;76(4):681–87. DOI:10.1136/annrheumdis-2016-210198; Lundberg I.E., Tjärnlund A., Bottai M. et al. International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955–64. DOI:10.1136/annrheumdis-2017-211468; Dimachkie M.M., Barohn R.J., Amato A. Idiopathic inflammatory myopathies. Neurol Clin 2014;32:595–628. DOI:10.1016/j.ncl.2014.04.007; Mammen A. Autoimmune muscle disease. Handbook of clinical neurology. 2016;133:467–84. DOI: 1016/B978-0-444-63432-0.00025-6; Kassardjian C.D, Lennon V.A., Alfugham N.B. et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 2015;72:996–1003. DOI:10.1001/jamaneurol.2015.1207; Kim H.I., Chung S.H., Hwang J.E. et al. Dermatomyositis associated with cancer of unknown primary site. J Korean Med Sci 2007;22 Suppl(Suppl):S174–7. DOI:10.3346/jkms.2007.22.S.S174; Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21(10):1855–9.; Hill C.L., Zhang Y., Sigurgeirsson B. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357(9250):96–100. DOI:10.1016/S0140-6736(00)03540-6; Allenbach Y., Keraen J., Bouvier A.M. et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016;139(Pt 8):2131–5. DOI:10.1093/brain/aww054; Pinal-Fernandez I., Parks C., Werner J.L. et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 2017;69(2):263–70. DOI:10.1002/acr.22920; Watanabe Y., Uruha A., Suzuki S. et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosur Psychiatry 2016;87:1038–44. DOI:10.1136/jnnp-2016-313166; https://nmb.abvpress.ru/jour/article/view/545